Clinical Trial: A Phase 2 Study of ABSK043 Combined With Osimertinib

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07710612) titled 'A Phase 2 Study of ABSK043 Combined With Osimertinib' on July 14.

Brief Summary: This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive

Intervention: DRUG: ABSK043 in combination with Osimertinib

Three potential dose levels of ABSK043 are prespecified, and Osimertinib will be administered orally at a fixed dose of 80 mg QD in escalation cohort.

Patients in...